Sirius Therapeutics has completed nearly $50 million in Series B2 financing to advance clinical development of the company’s novel siRNA therapeutics for cardiometabolic disorders and continue innovation of its RNA delivery technologies. A renowned corporate venture capital firm led the financing round, which was joined by a new investor (BioTrack Capital) and existing investors OrbiMed, Creacion Ventures, and Hankang Capital.
CEO Dr. Qunsheng Ji pointed out that the company has three clinical-stage programs and a deep preclinical pipeline. And the most advanced compound, SRSD107, is a long-acting, next-generation anticoagulant for thromboembolic disorders poised to begin Phase 2 clinical development in Europe.
The company also recently applied to the European Medicines Agency (EMA) to initiate a Phase II trial. Sirius has also received approval from the U.S. FDA and the China NMPA and has started Phase 1 studies with SRSD216, a novel siRNA therapeutic for hyperlipoproteinemia in patients with atherosclerotic cardiovascular disease. SRSD101, the company’s siRNA therapeutic for dyslipidemia, is undergoing Phase 1 clinical trials in China.
KEY QUOTE:
“The successful completion of our Series B2 financing is a strong endorsement of our progress to date and our strategy going forward. We are deeply grateful to our new and existing investors for their continued support. The funds from this round will further advance our clinical programs and expand our pipeline, to deliver “transformative siRNA therapeutics for patients with chronic diseases” around the world.”
Dr. Qunsheng Ji, CEO of Sirius Therapeutics
